Wockhardt Becomes First Indian Drug Maker to Receive EMR

Law360, New York (December 28, 2003, 12:00 AM EST) -- Wockhardt Ltd. became the first domestic Indian drug maker to secure an exclusive marketing right last week after the Controller General of Patents and Trademarks granted an EMR for its topical anti-bacterial drug Nadoxin (Nadifloxacin).

Nadoxin is a treatment against a wide spectrum of topical bacterial infections. A post-marketing surveillance study conducted on 696 patients across the country has established a 99% success rate for Nadoxin, the company said.

Wockhardt is only the second pharmaceutical company to receive an EMR after Novartis secured rights for its...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.